0.68
price down icon11.69%   -0.09
after-market Handel nachbörslich: .69 0.010 +1.47%
loading
Schlusskurs vom Vortag:
$0.77
Offen:
$0.7231
24-Stunden-Volumen:
2.42M
Relative Volume:
1.06
Marktkapitalisierung:
$77.93M
Einnahmen:
$13.45M
Nettoeinkommen (Verlust:
$-178.23M
KGV:
-0.4121
EPS:
-1.65
Netto-Cashflow:
$-132.53M
1W Leistung:
-22.87%
1M Leistung:
-33.98%
6M Leistung:
-78.21%
1J Leistung:
-90.30%
1-Tages-Spanne:
Value
$0.68
$0.7388
1-Wochen-Bereich:
Value
$0.68
$0.891
52-Wochen-Spanne:
Value
$0.68
$7.345

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
Firmenname
Fate Therapeutics Inc
Name
Telefon
858.875.1803
Name
Adresse
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
Mitarbeiter
0
Name
Twitter
@fatethx
Name
Nächster Verdiensttermin
2025-03-05
Name
Neueste SEC-Einreichungen
Name
FATE's Discussions on Twitter

Vergleichen Sie FATE mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
FATE
Fate Therapeutics Inc
0.68 77.93M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
484.01 124.29B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
610.64 68.39B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
590.06 35.99B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
262.16 33.93B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
264.32 28.47B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-11-18 Hochstufung BofA Securities Underperform → Neutral
2024-06-17 Hochstufung Piper Sandler Neutral → Overweight
2023-03-27 Fortgesetzt Wells Fargo Equal Weight
2023-01-24 Herabstufung H.C. Wainwright Buy → Neutral
2023-01-06 Herabstufung BMO Capital Markets Outperform → Market Perform
2023-01-06 Herabstufung BofA Securities Buy → Underperform
2023-01-06 Herabstufung Cowen Outperform → Market Perform
2023-01-06 Herabstufung Piper Sandler Overweight → Neutral
2023-01-06 Herabstufung Stifel Buy → Hold
2023-01-06 Herabstufung Truist Buy → Hold
2023-01-06 Herabstufung Wedbush Outperform → Neutral
2023-01-03 Herabstufung Guggenheim Buy → Neutral
2022-12-22 Herabstufung Oppenheimer Outperform → Perform
2022-12-15 Eingeleitet Goldman Sell
2022-11-04 Fortgesetzt Cantor Fitzgerald Overweight
2022-10-10 Eingeleitet Canaccord Genuity Buy
2022-08-18 Fortgesetzt Wells Fargo Overweight
2022-07-28 Eingeleitet Needham Hold
2022-07-11 Hochstufung BMO Capital Markets Market Perform → Outperform
2022-06-03 Eingeleitet Robert W. Baird Neutral
2022-02-11 Fortgesetzt BMO Capital Markets Market Perform
2021-12-15 Hochstufung Wedbush Neutral → Outperform
2021-12-07 Eingeleitet Cowen Outperform
2021-11-09 Hochstufung Citigroup Neutral → Buy
2021-08-26 Eingeleitet Morgan Stanley Equal-Weight
2021-06-07 Hochstufung H.C. Wainwright Neutral → Buy
2021-05-07 Hochstufung Wedbush Neutral → Outperform
2021-04-26 Fortgesetzt Jefferies Buy
2021-02-26 Eingeleitet BofA Securities Buy
2021-02-26 Herabstufung Wedbush Outperform → Neutral
2021-02-11 Herabstufung Citigroup Buy → Neutral
2021-01-27 Fortgesetzt H.C. Wainwright Neutral
2020-05-13 Eingeleitet H.C. Wainwright Buy
2020-03-04 Eingeleitet Barclays Overweight
2020-01-09 Herabstufung BMO Capital Markets Outperform → Market Perform
2019-12-30 Bestätigt Mizuho Buy
2019-12-09 Hochstufung Wells Fargo Market Perform → Outperform
2019-11-12 Eingeleitet SunTrust Buy
2019-11-06 Herabstufung Wells Fargo Outperform → Market Perform
2019-10-01 Eingeleitet Stifel Buy
2019-08-09 Eingeleitet BTIG Research Buy
2019-07-22 Eingeleitet Cantor Fitzgerald Overweight
2019-07-12 Eingeleitet Oppenheimer Outperform
2019-06-13 Eingeleitet Mizuho Buy
2019-06-07 Eingeleitet ROTH Capital Neutral
2019-05-31 Eingeleitet Guggenheim Buy
2019-05-24 Fortgesetzt Citigroup Buy
2019-03-28 Eingeleitet SVB Leerink Outperform
2019-01-03 Herabstufung Stephens Overweight → Equal-Weight
2018-11-05 Eingeleitet Jefferies Buy
2018-08-01 Eingeleitet Citigroup Buy
2018-03-06 Herabstufung H.C. Wainwright Buy → Neutral
Alle ansehen

Fate Therapeutics Inc Aktie (FATE) Neueste Nachrichten

pulisher
Apr 02, 2025

FATE CLASS ACTION: Hagens Berman Encourages Fate Therapeutics, Inc. (FATE) Investors with Significant Losses to Contact Firm’s Attorneys, Securities Fraud Lawsuit Pending - ACCESS Newswire

Apr 02, 2025
pulisher
Apr 02, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Apr 02, 2025
pulisher
Apr 02, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.

Apr 02, 2025
pulisher
Mar 21, 2025

Equities Analysts Issue Forecasts for FATE FY2025 Earnings - Defense World

Mar 21, 2025
pulisher
Mar 21, 2025

Weekly Research Analysts’ Ratings Updates for Fate Therapeutics (FATE) - Defense World

Mar 21, 2025
pulisher
Mar 13, 2025

Fate Therapeutics Inc. Faces Global Expansion Challenges Amid Political and Economic Uncertainties - MSN

Mar 13, 2025
pulisher
Mar 13, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Recommendation of “Hold” from Analysts - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook By Investing.com - Investing.com South Africa

Mar 12, 2025
pulisher
Mar 12, 2025

Fate Therapeutics’ SWOT analysis: promising pipeline drives stock outlook - Investing.com

Mar 12, 2025
pulisher
Mar 12, 2025

Fate Therapeutics at Leerink Conference: Strategic Shift to FT-819 By Investing.com - Investing.com UK

Mar 12, 2025
pulisher
Mar 11, 2025

Fate Therapeutics at Barclays Conference: Strategic Shift to Autoimmune Focus - Investing.com UK

Mar 11, 2025
pulisher
Mar 11, 2025

Fate Therapeutics (NASDAQ:FATE) Rating Lowered to “Sell” at StockNews.com - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

Fate Therapeutics price target lowered to $2.50 from $3 at BofA - TipRanks

Mar 10, 2025
pulisher
Mar 10, 2025

Q1 EPS Estimates for Fate Therapeutics Boosted by Wedbush - Defense World

Mar 10, 2025
pulisher
Mar 08, 2025

Fate Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire

Mar 08, 2025
pulisher
Mar 08, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Just Reported, And Analysts Assigned A US$6.00 Price Target - Yahoo Finance

Mar 08, 2025
pulisher
Mar 08, 2025

Stifel Nicolaus Lowers Fate Therapeutics (NASDAQ:FATE) Price Target to $3.00 - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Wedbush Reaffirms Neutral Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Needham & Company LLC Reiterates Hold Rating for Fate Therapeutics (NASDAQ:FATE) - Defense World

Mar 08, 2025
pulisher
Mar 08, 2025

Wells Fargo & Company Has Lowered Expectations for Fate Therapeutics (NASDAQ:FATE) Stock Price - Defense World

Mar 08, 2025
pulisher
Mar 07, 2025

Is Fate Therapeutics Inc (NASDAQ: FATE) A Good Investment For New Investors Now? - Stocks Register

Mar 07, 2025
pulisher
Mar 07, 2025

Optimistic Outlook for Fate Therapeutics’ FT819 in Cell-Therapy Space Amid Promising Phase 1 Results - TipRanks

Mar 07, 2025
pulisher
Mar 07, 2025

Cautious Outlook on Fate Therapeutics Amid FT819 Program Developments and Financial Uncertainties - TipRanks

Mar 07, 2025
pulisher
Mar 06, 2025

Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Stifel cuts Fate Therapeutics stock target to $3, maintains hold By Investing.com - Investing.com Canada

Mar 06, 2025
pulisher
Mar 06, 2025

Cautious Optimism: Hold Rating for Fate Therapeutics Amid Early-Stage Progress and Market Uncertainties - TipRanks

Mar 06, 2025
pulisher
Mar 06, 2025

FATE Q4 Earnings Beat, Autoimmunity, Oncology Programs in Focus - Nasdaq

Mar 06, 2025
pulisher
Mar 06, 2025

Jefferies cuts Fate Therapeutics target to $8, keeps Buy rating - Investing.com India

Mar 06, 2025
pulisher
Mar 06, 2025

Y Intercept Hong Kong Ltd Invests $58,000 in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Mar 06, 2025
pulisher
Mar 06, 2025

Fate Therapeutics: Q4 Earnings Snapshot - mySA

Mar 06, 2025
pulisher
Mar 05, 2025

Fate Therapeutics Advances CAR T-cell Programs Amid Financial Losses - TipRanks

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics (FATE) Reports Q4 Loss, Tops Revenue Estimates - MSN

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics shares rise as Q4 revenue tops estimates By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics shares rise as Q4 revenue tops estimates - Investing.com

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics earnings matched, revenue topped estimates By Investing.com - Investing.com UK

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics, Inc Q4 Loss Misses Estimates - Nasdaq

Mar 05, 2025
pulisher
Mar 05, 2025

Fate Therapeutics: Q4 Earnings Snapshot -March 05, 2025 at 04:13 pm EST - Marketscreener.com

Mar 05, 2025
pulisher
Mar 05, 2025

FATE THERAPEUTICS INC SEC 10-K Report - TradingView

Mar 05, 2025
pulisher
Mar 05, 2025

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 05, 2025
pulisher
Mar 04, 2025

Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mar 04, 2025
pulisher
Mar 04, 2025

Fate Therapeutics (NASDAQ:FATE) Upgraded by StockNews.com to Hold Rating - Defense World

Mar 04, 2025
pulisher
Feb 28, 2025

FATE stock touches 52-week low at $1.03 amid sharp annual decline - Investing.com

Feb 28, 2025
pulisher
Feb 25, 2025

Fate Therapeutics (FATE) Expected to Announce Earnings on Monday - MarketBeat

Feb 25, 2025
pulisher
Feb 22, 2025

Fate Therapeutics (FATE) Projected to Post Earnings on Monday - Defense World

Feb 22, 2025
pulisher
Feb 20, 2025

iTeos Therapeutics (NASDAQ:ITOS) & Fate Therapeutics (NASDAQ:FATE) Head-To-Head Analysis - Defense World

Feb 20, 2025
pulisher
Feb 20, 2025

Fate Therapeutics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire

Feb 20, 2025
pulisher
Feb 19, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $6.75 Average PT from Analysts - Armenian Reporter

Feb 19, 2025
pulisher
Feb 18, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Given Consensus Rating of "Hold" by Brokerages - MarketBeat

Feb 18, 2025

Finanzdaten der Fate Therapeutics Inc-Aktie (FATE)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$67.48
price down icon 1.23%
$73.33
price down icon 0.15%
$31.79
price up icon 1.63%
$18.91
price down icon 7.58%
$92.01
price down icon 1.40%
biotechnology ONC
$264.32
price down icon 3.81%
Kapitalisierung:     |  Volumen (24h):